UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metronomic Chemotherapy

Cancers, 2021-05, Vol.13 (9), p.2236

2021

Volltextzugriff (PDF)

An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective

International journal of molecular sciences, 2023-07, Vol.24 (15), p.11890

2023

Volltextzugriff (PDF)

Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study

BMC public health, 2022-11, Vol.22 (1), p.2137-2137, Article 2137

2022

Volltextzugriff (PDF)

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells

International journal of molecular sciences, 2023-11, Vol.24 (22), p.16294

2023

Volltextzugriff (PDF)

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything

Cancers, 2022-07, Vol.14 (15), p.3729

2022

Volltextzugriff (PDF)

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

Frontiers in oncology, 2023-10, Vol.13, p.1247270-1247270

2023

Volltextzugriff (PDF)

Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation

Frontiers in oncology, 2022-11, Vol.12, p.998274-998274

2022

Volltextzugriff (PDF)

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows

Journal of clinical medicine, 2022-08, Vol.11 (16), p.4710

2022

Volltextzugriff (PDF)

Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report

Current problems in cancer. Case reports, 2022-06, Vol.6, p.100167, Article 100167

2022

Volltextzugriff (PDF)

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Breast care (Basel, Switzerland), 2020-02, Vol.15 (1), p.30-37

2020

Volltextzugriff (PDF)

Metronomic chemotherapy for advanced breast cancer patients

Cancer letters, 2017-08, Vol.400, p.252-258

2017

Volltextzugriff (PDF)

Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic

European journal of clinical pharmacology, 2022-11, Vol.78 (11), p.1791-1800

2022

Volltextzugriff (PDF)

First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e13064-e13064

2023

Volltextzugriff (PDF)

Liver toxicity associated to novel cyclin-dependent kinase inhibitor ribociclib in a cohort of advanced breast cancer patients

Journal of hepatology, 2022-07, Vol.77, p.S404-S405

2022

Volltextzugriff (PDF)

The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients

Anti-cancer drugs, 2022-01, Vol.33 (1), p.e628-e634

2022

Volltextzugriff (PDF)

Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project

Clinical breast cancer, 2021-10, Vol.21 (5), p.e547-e560

2021

Volltextzugriff (PDF)

Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.GS3-07-GS3-07

2022

Volltextzugriff (PDF)

Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL

Cancer research (Chicago, Ill.), 2022-02, Vol.82 (4_Supplement), p.OT2-19-06-OT2-19-06

2022

Volltextzugriff (PDF)

Is metronomic vinorelbine (mVRL) able to inhibit both HUVEC and triple-negative breast cancer (TNBC) cells? The proof-of-concept VICTOR-0 study

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e14014-e14014

2017

Volltextzugriff (PDF)

Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study

Journal of clinical oncology, 2019-05, Vol.37 (15_suppl), p.e12549-e12549

2019

Volltextzugriff (PDF)

Abstract P5-07-10: Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P5-P5-07-10

2020

Volltextzugriff (PDF)

Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale

European journal of cancer care, 2021-01, Vol.30 (1), p.e13334-n/a

2021

Volltextzugriff (PDF)

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

OncoTargets and therapy, 2019-04, Vol.12, p.2989-2997

2019

Volltextzugriff (PDF)

1 – 25 von 67

Suche als RSS-Feed

Aktive Filter

ThemaPatients

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(67)

Sprache

Englisch
(67)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Metronomic Chemotherapy

An Overview of PARP Resistance in Ovarian Cancer from a Molecular and Clinical Perspective

Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study

TWIST1 Upregulation Is a Potential Target for Reversing Resistance to the CDK4/6 Inhibitor in Metastatic Luminal Breast Cancer Cells

Personalised Therapies for Metastatic Triple-Negative Breast Cancer: When Target Is Not Everything

Late onset toxicities associated with the use of CDK 4/6 inhibitors in hormone receptor positive (HR+), human epidermal growth factor receptor-2 negative (HER2-) metastatic breast cancer patients: a multidisciplinary, pan-EU position paper regarding their optimal management. The GIOCONDA project

Co-targeting triple-negative breast cancer cells and endothelial cells by metronomic chemotherapy inhibits cell regrowth and migration via downregulation of the FAK/VEGFR2/VEGF axis and autophagy/apoptosis activation

Metronomic Chemotherapy for Metastatic Breast Cancer Treatment: Clinical and Preclinical Data between Lights and Shadows

Exceptional disease control with neratinib monotherapy in HER2-positive advanced breast cancer: A case report

Is There Still a Role for Endocrine Therapy Alone in HR+/HER2– Advanced Breast Cancer Patients? Results from the Analysis of Two Data Sets of Patients Treated with High-Dose Fulvestrant as First-Line Therapy in the Real-World Setting: The EVA and GIM-13 AMBRA Studies

Metronomic chemotherapy for advanced breast cancer patients

Why not? Motivations for entering a volunteer register for clinical trials during the COVID-19 pandemic

First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study

Liver toxicity associated to novel cyclin-dependent kinase inhibitor ribociclib in a cohort of advanced breast cancer patients

The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patients

Managing Menopausal Symptoms in Young Women With Breast Cancer: When Medicine Is Not All. The Take Care Project

Abstract GS3-07: Circulating tumor DNA (ctDNA) dynamics in patients with hormone receptor positive (HR+)/HER2 negative (HER2-) advanced breast cancer (aBC) treated in first line with ribociclib (R) and letrozole (L) in the BioItaLEE trial

Abstract OT2-19-06: Phase 2 study of abemaciclib in combination with endocrine therapy with or without paclitaxel induction in patients with hormone receptor-positive, HER2-negative advanced breast cancer and aggressive disease criteria: ABIGAIL

Is metronomic vinorelbine (mVRL) able to inhibit both HUVEC and triple-negative breast cancer (TNBC) cells? The proof-of-concept VICTOR-0 study

Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study

Abstract P5-07-10: Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents. Results from the GIM-13 AMBRA study

Abstract P5-01-07: Bioitalee - Biomarker analysis on liquid biopsies of patients treated with ribociclib and letrozole as first-line therapy for advanced breast cancer (aBC) (NCT03439046)

Validation of the Italian version of the full and abbreviated Trust in Oncologist Scale

Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?

Aktive Filter

Suchergebnisse filtern